Ingelheim, Germany, 20 February 2025 – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial ...

“That’s why it’s really important to seek medical attention because one symptom alone doesn’t diagnose you with one or the other of these,” said Neha Vyas, MD, family medicine physician ...

SoCheers has announced the appointment of Prashant Vyas as Head - People Growth & Culture. He will be based in the Agency’s Mumbai office. With over 15 years of experience in human resources ...

An architect by profession, he transitioned to cricket at 25. He and his wife Neha Khedekar, who prefers keeping her life private, married in 2020 and have a son named Aathman.

ACKO Drive has appointed Neha Bareja as the Head of Marketing. Neha Bareja was earlier Senior Director - Content and Influencer Marketing at ACKO. Before ACKO, she was with Meesho as Head - Social ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Roche and Boehringer Ingelheim have both formed partnerships with tech companies this week to develop and deploy wearable biosensor technology for use in clinical trials and patient monitoring ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist BI 456906, setting up a possible challenge to emerging therapies ...

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...

Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor ...